Antisense Therapeutics Ltd. announced that ATL1103 on track to move Into clinical development. The Company has now completed repeat-dosing toxicology studies for ATL1103 in two species--mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103. ATL1103 is a second-generation antisense drug that targets the growth hormone receptor (GHR). By blocking the action of GHR, ATL1103 inhibits production of insulin-like growth factor-1 (IGF-I) from the liver thereby reducing its levels in the blood. GHR is a clinically validated therapeutic target in the growth disorder acromegaly (excessive growth of parts of the body and organs including the liver, kidney and heart) where the goal of treatment is to normalise IGF-1 levels in the blood. There is a clear need for better treatments for this niche and difficult to treat disease with the size of this market nearing $1 billion per annum in drug sales.

Antisense Therapeutics Ltd., Annual General Meeting, Nov 13, 2009, at 11:00 EAST-East Australian Standard GST. Location: Computershare Conference Centre, Yarra Falls, 452 Johnston Street, Abbotsford, Victoria, Australia. Agenda: To receive and consider the annual report of the company for the year ended June 30, 2009, comprising the directors report, financial statements and auditors report; to approve the re-election of non-executive director-Professor George Werther; and to approve non-binding resolution to adopt remuneration report.

To provide an overview of the company's drug development pipeline with focus on the company's lead compound, ATL/TV1102 for Multiple Sclerosis (MS), which has been licensed to Teva Pharmaceutical Industries